Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of tocilizumab in giant cell arteritis
2011-006022-25Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Tocilizumab + prednisone taper with Placebo + prednisone taper (2 arms). Primary endpoint: Sustained remission at Week 52 (primary). Started Mar 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2011-006022-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006022-25.